Improving time to start bone modifying agents in newly diagnosed multiple myeloma patients.

65Background: Current ASCO and IMWG guidelines recommend all patients (pts) on active myeloma therapy receive concurrent supportive care with a bone modifying agent (BMA) to decrease the risk of sk...